Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1045 results
February 2016
-
Media ReleaseFDA approves new indication for Novartis drug Afinitor® for progressive, nonfunctional GI and lung neuroendocrine tumors (NET)In advanced progressive, nonfunctional NET, Afinitor is the first approved treatment for patients with lung NET and the first oral therapy for GI NET Approval helps fulfill unmet need as…
-
Media ReleaseNovartis shareholders approve all resolutions proposed by Board of DirectorsShareholders approve 19th consecutive dividend increase to CHF 2.70 (+4%) per share for 2015 Dr. Joerg Reinhardt confirmed by shareholders as Chairman of the Novartis Board of Directors as well as…
-
Media ReleaseNovartis drug PKC412 (midostaurin) receives Breakthrough Therapy designation from the FDA for newly-diagnosed FLT3-mutated acute myeloid leukemia (AML)PKC412 (midostaurin) significantly improved overall survival of adult patients eligible to receive standard induction and consolidation chemotherapy AML has the lowest survival rate of all adult…
-
Media ReleaseAlcon expands leadership position in treating glaucoma through acquisition of Transcend Medical, Inc.Acquisition to add minimally-invasive glaucoma surgery (MIGS) device to pipeline, expanding Alcon's surgical presence in a new category to treat glaucoma The goal of MIGS is to reduce or…
-
Media ReleaseSandoz strengthens its biosimilars portfolio with acquisition of Pfizer's biosimilar infliximab in EEASandoz acquires rights to PF-06438179 (biosimilar infliximab) in the European Economic Area (EEA)* Sandoz plans to complete Phase III development program and file for registration in the EU…
-
Media ReleaseSandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastimSandoz' late-stage biosimilar pipeline gains momentum with sustained investment - five of 10 planned regulatory filings achieved Sandoz believes that the totality of evidence in its submission,…
January 2016
-
Media ReleaseNovartis Foundation commemorates World Leprosy Day with its continued efforts to go the last mile toward elimination2016 marks 30 years of commitment by the Novartis Foundation to support people affected by leprosy and to end this ancient disease New strategy from the Novartis Foundation to accelerate…
-
Media ReleaseNovartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operationsStrong growth (cc) in full year sales, core operating income and core EPS[2] Net sales up 5% (cc) and core operating income up 10% (cc) Core operating income margin up 1.3 percentage points (…
-
Media ReleaseNovartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the USCosentyx is the first and only interleukin-17A (IL-17A) inhibitor approved for adult patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) FDA approval for Cosentyx is…
-
Media ReleaseNovartis continues to grow immuno-oncology pipeline through collaboration and licensing agreement with Surface OncologyAgreement gives Novartis access to four pre-clinical programs that target regulatory T cell populations, inhibitory cytokines, and immunosuppressive metabolites in the tumor microenvironment…
-
Media ReleaseNovartis Pharmaceuticals collaborates with Qualcomm in digital innovation with the Breezhaler(TM) inhaler device to treat COPDThe Breezhaler(TM) inhaler is the device for Novartis' portfolio of COPD treatments of Onbrez and Seebri, and Ultibro, the leading LABA/LAMA treatment The collaboration further supports Novartis'…
Pagination
- ‹ Previous page
- 1
- …
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- …
- 88
- › Next page